LIVN241220C30000
- 0.00
- 0.000.00%
LivaNova Newsroom
Is Now The Time To Look At Buying LivaNova PLC (NASDAQ:LIVN)?
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know
LivaNova's OSPREY Sleep Apnea Trail on Aura6000 Meets Primary Endpoint
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
Barclays Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $61
Barclays Releases a Hold Rating on LivaNova (LIVN)
Mizuho Securities Maintains LivaNova(LIVN.US) With Buy Rating
LivaNova's OSPREY Trial Success Drives Buy Recommendation Amid Market Potential
Solid Earnings Reflect LivaNova's (NASDAQ:LIVN) Strength As A Business
Express News | LivaNova PLC - No Serious Adverse Device-Related or Procedure-Related Events Reported
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
Express News | LivaNova Announces Osprey Clinical Study Meets Primary Safety and Efficacy Endpoints
How Much Upside Is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%
Is a LivaNova PLC (LIVN) Promising Medical Stock With Growth Potential?
Earnings Beat: LivaNova PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Express News | LivaNova PLC: Co Will Continue to Pursue Reimbursement Opportunities for Vns Therapy for Dre
Express News | LivaNova PLC: CMS Maintains Vns Therapy for Dre at Level 5 Apc Under 2025 Medicare Hospital Outpatient Prospective Payment System
A Quick Look at Today's Ratings for LivaNova(LIVN.US), With a Forecast Between $70 to $75
LivaNova | 10-Q: Q3 2024 Earnings Report
LivaNova Is Maintained at Outperform by Mizuho